A small study found that patients with metastatic renal cell carcinoma (mRCC) who discontinue nivolumab due to immune-related adverse events can continue to derive benefit even after cessation of therapy.
Specific tumor genotypes could represent distinct subtypes of clear cell renal cell carcinoma, according to a new analysis of the RECORD-3 trial. Genotyping could potentially help guide treatment decisions if the results can be validated.
The use of immune checkpoint inhibitors as adjuvant or neoadjuvant therapy in kidney cancer could offer important new treatment options. Questions remain, though, on the timing and sequence of therapy.
The combination of bevacizumab and an investigational nanoparticle-drug conjugate known as CRLX101 failed to improve outcomes in metastatic renal cell carcinoma compared with standard of care.
Expression of MET as measured by immunohistochemistry was not associated with any difference in the performance of cabozantinib as compared with everolimus in patients with advanced renal cell carcinoma.
Radiotherapy in advanced kidney cancer is generally only used in select metastatic settings, but the use of stereotactic ablative radiotherapy offers promise in a number of indications in this malignancy.
Active surveillance of small renal masses has been shown in recent years to be a generally safe and reasonable approach, though there are a number of factors for clinicians to keep in mind in taking this path.
The addition of the IMA901 vaccine to sunitinib for the first-line treatment of metastatic renal cell carcinoma did not improve overall survival.
Treatment with cabozantinib resulted in significantly improved PFS and overall response vs sunitinib for patients with metastatic renal cell carcinoma.
Patients with renal cell carcinoma at high risk for recurrence had prolonged disease-free survival when treated with sunitinib compared with placebo.